3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Status
Completed
3
Unknown
1
Suspended
1
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Endocrine
49
NET
11
Gastrointestinal
11
Thoracic
10
Head & Neck
5
Gynecologic
5
Dermatologic
5
Sarcoma
3
Other solid neoplasm
3
Lymphoid
3
Genitourinary
3
Breast
3
CNS
2
Conditions
Lymphoma
1600
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1282
Lymphoma, Non-Hodgkin
1231
Leukemia, Lymphocytic, Chronic, B-Cell
1090
Lymphoma, Follicular
979
Lymphoma, Large B-Cell, Diffuse
853
Leukemia
790
Hodgkin Disease
777
Lymphoma, Mantle-Cell
675
Leukemia, Myeloid, Acute
540
Burkitt Lymphoma
507
Lymphoma, B-Cell, Marginal Zone
490
Multiple Myeloma
483
Myelodysplastic Syndromes
371
Lymphoma, Large-Cell, Immunoblastic
366
Recurrence
363
Lymphoma, T-Cell, Cutaneous
313
Neoplasms
309
Waldenstrom Macroglobulinemia
307
Lymphoma, Large-Cell, Anaplastic
254
Mycosis Fungoides
252
Lymphoma, B-Cell
231
Sezary Syndrome
229
Blast Crisis
210
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
208
Myeloproliferative Disorders
205
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
189
Neoplasms, Plasma Cell
188
Leukemia, Myeloid, Accelerated Phase
186
Leukemia, Myeloid, Chronic-Phase
179
Interventions
pembrolizumab
1
avelumab
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Neuroendocrine
×
Lymphoid
×
Clear all
NCT03012620
2024-02-28
AcSé
UNICANCER
Phase 2
Completed
334 enrolled
NCT02113800
2020-10-28
EVINEC
AIO-Studien-gGmbH
Phase 2
Completed
40 enrolled
NCT03147404
2019-12-30
MS100070-0177
Samsung Medical Center
Phase 2
Completed
14 enrolled